Eneh Stralina, Hartikainen Jaana M, Heikkinen Sami, Sironen Reijo, Tengström Maria, Kosma Veli-Matti, Ahuja Saket, Mannermaa Arto
Institute of Clinical Medicine, Clinical Pathology and Forensic Medicine, School of Medicine, University of Eastern Finland, Kuopio, Finland.
Multidisciplinary Cancer Research Community (Cancer RC), University of Eastern Finland, Kuopio, Finland.
PLoS One. 2025 Apr 29;20(4):e0322179. doi: 10.1371/journal.pone.0322179. eCollection 2025.
Estrogen receptor-positive (ER+) breast cancers (BC) cause death despite well-established treatments. MicroRNAs (miRNAs) have potential as biomarkers specific to cancer subtypes and tissues, therefore miRNA-based biomarkers could help improve patient survival. In this study, we investigated a relatively unknown miRNA, miR-7974. We utilized small RNA data from 204 breast tissue samples to study miR-7974 association with clinicopathological features and outcomes for BC patients. Additionally, in vitro and in ovo methods were used to identify miR-7974 role at molecular and cellular level in MCF-7 cells. Findings were validated using MDA-MB-453 cells. MiR-7974 was upregulated in many clinicopathological features of BC (P<0.05). Furthermore, the highest expression of miR-7974 was associated with poor relapse-free survival in ER+ BC patients [hazard ratio (HR)=8.70; 95% confidence interval (CI)=3.28-23.06; P=1.37x10-05] and poor BC-specific survival in patients receiving only surgical treatment (HR=8.36; 95% CI=1.01-69.06; P=0.049). Our studies revealed that miR-7974 targets autophagy gene, MAP1LC3B, identified as direct miR-7974 target (P<0.05) in MCF-7 cells. In vitro analyses indicated overexpressing miR-7974 had anti-proliferative effect in MCF7 and MDA-MB-453 cells. Overall, our results demonstrate potential prognostic role of miR-7974 in ER+ BC.
尽管有成熟的治疗方法,但雌激素受体阳性(ER+)乳腺癌(BC)仍会导致死亡。微小RNA(miRNA)有潜力成为癌症亚型和组织特异性的生物标志物,因此基于miRNA的生物标志物有助于提高患者生存率。在本研究中,我们调查了一种相对不为人知的miRNA,即miR-7974。我们利用来自204个乳腺组织样本的小RNA数据,研究miR-7974与BC患者临床病理特征及预后的相关性。此外,还采用体外和卵内方法,在分子和细胞水平上鉴定miR-7974在MCF-7细胞中的作用。研究结果在MDA-MB-453细胞中得到验证。miR-7974在BC的许多临床病理特征中上调(P<0.05)。此外,miR-7974的最高表达与ER+ BC患者无复发生存率低相关[风险比(HR)=8.70;95%置信区间(CI)=3.28-23.06;P=1.37×10-05],且与仅接受手术治疗患者的BC特异性生存率低相关(HR=8.36;95%CI=1.01-69.06;P=0.049)。我们的研究表明,miR-7974靶向自噬基因MAP1LC3B,在MCF-7细胞中该基因被鉴定为miR-7974的直接靶点(P<0.05)。体外分析表明,过表达miR-7974对MCF7和MDA-MB-453细胞具有抗增殖作用。总体而言,我们的结果证明了miR-7974在ER+ BC中的潜在预后作用。